公开(公告)号：KR101402921B1

公开(公告)日：2014-06-02

申请号：KR1020130102400

申请日：2013-08-28

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  윤철호 ,  박민 ,  윤일주

IPC: A61K31/05 ,  A61K31/09 ,  A61P3/04 ,  A61P3/10

Abstract: 본 발명은 비만 또는 제 2형 당뇨 치료를 위해 레스베라톨 유도체의 이용에 관한 것으로, 보다 상세하게는 피세아타놀(piceatannol), 피세이드(piceid) 또는 프테로스틸벤(pterostilbene)은 TREM-2 억제제로 작용할 수 있으며, 이에 의해 비만 또는 제 2형 당뇨의 예방 또는 치료에 이용할 수 있다. 또한 TREM-2(Triggering Receptor Expressed on Myeloid cells-2)를 억제함으로써 인슐린 대사와 관련된 유전자 및 지방세포 분화와 관련된 유전자의 발현조절을 제어할 수 있어 효과적으로 비만 또는 제 2형 당뇨를 치료하는데 유용하게 사용될 수 있는 장점이 있다.

公开(公告)号：KR1020120112973A

公开(公告)日：2012-10-12

申请号：KR1020110030606

申请日：2011-04-04

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  이자운 ,  윤철호 ,  김소영 ,  박민

IPC: A61K31/05 ,  A61K31/045 ,  A61K31/09 ,  A61P3/04

Abstract: PURPOSE: A composition containing TREM-2 inhibitors or resveratol is provided to control the expression of insulin metabolism-related genes and adipocyte differentiation-related genes and to effectively treat obesity or type 2 diabetes. CONSTITUTION: A composition for preventing or treating obesity contains TREM-2(triggering receptor expressed on myeloid cells-2) inhibitors as an active ingredient. The TREM-2 inhibitor is a compound of piceatannol, piceid, or pterostilbene. A composition for preventing or treating obesity or type 2 diabetes contains piceatannol, piceid, or pterostilbene compounds as an active ingredient. The composition for preventing or treating obesity or type 2 diabetes contains a resveratol derivative as an active ingredient.

Abstract translation: 目的：提供含有TREM-2抑制剂或白藜芦醇的组合物，以控制胰岛素代谢相关基因和脂肪细胞分化相关基因的表达，并有效治疗肥胖或2型糖尿病。 构成：用于预防或治疗肥胖症的组合物含有TREM-2（触发骨髓细胞-2表达受体）抑制剂作为活性成分。 TREM-2抑制剂是吡草胺，piceid或p芪烯的化合物。 用于预防或治疗肥胖症或2型糖尿病的组合物含有作为活性成分的皮沙替坦，皮质或p芪烯化合物。 用于预防或治疗肥胖症或2型糖尿病的组合物含有白藜芦醇衍生物作为活性成分。

公开(公告)号：KR101084529B1

公开(公告)日：2011-11-18

申请号：KR1020090015390

申请日：2009-02-24

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  이기모 ,  박민 ,  윤철호

IPC: A61K38/20 ,  A61K48/00 ,  A61P9/12 ,  A61P9/04

Abstract: 본 발명은 인터루킨-24, 인터루킨-24의 아고니스트 또는 인터루킨-24를 암호화하는 유전자를 유효성분으로 포함하는 고혈압 또는 그의 합병증의 예방 또는 치료용 조성물에 관한 것이다. 또한 본 발명은 상기 조성물을 이용한 고혈압 또는 그의 합병증의 예방 또는 치료방법에 관한 것이다. 본 발명의 조성물은 고혈압관련 유전자들의 발현을 억제함으로써 효과를 발휘한다.
인터루킨-24, IL-24, 고혈압, 인터루킨-24 아고니스트

公开(公告)号：KR1020100096489A

公开(公告)日：2010-09-02

申请号：KR1020090015390

申请日：2009-02-24

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  이기모 ,  박민 ,  윤철호

IPC: A61K38/20 ,  A61K48/00 ,  A61P9/12 ,  A61P9/04

CPC classification number: A61K38/20 ,  C07K14/54 ,  C12N15/63 ,  Y10S514/824

Abstract: PURPOSE: A pharmaceutical composition containing interleukin, interleukin-24 agonist or gene encoding interleukin-24 is provided to treat or prevent hypertension or hypertension complication by suppressing expression of hypertension-associated gene. CONSTITUTION: A composition for preventing or treating hypertension contains interleukin-24, interleukin-24 agonist, gene encoding interleukin-24, mutant, or complement thereof. A gene encoding interleukin-24 is contained in viral or non-viral transporter. The composition additionally contains other material for treating hypertension.

Abstract translation: 目的：提供含有白介素，白细胞介素-24激动剂或编码白介素24的基因的药物组合物，通过抑制高血压相关基因的表达来治疗或预防高血压或高血压并发症。 构成：用于预防或治疗高血压的组合物含有白细胞介素-24，白细胞介素-24激动剂，编码白细胞介素-24，突变体或其补体的基因。 编码白细胞介素-24的基因包含在病毒或非病毒转运蛋白中。 该组合物另外含有用于治疗高血压的其它材料。

公开(公告)号：KR1020150010326A

公开(公告)日：2015-01-28

申请号：KR1020130085180

申请日：2013-07-19

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  박민 ,  윤일주 ,  정윤화 ,  김상희 ,  강건욱 ,  임채민

IPC: A61K31/34 ,  A61K31/166 ,  A61K31/16 ,  A61P3/04

Abstract: The present invention relates to a composition for preventing or treating obesity and type 2 diabetes, or hepatic steatosis and, more specifically, to a composition for preventing or treating obesity and type 2 diabetes, or hepatic steatosis, containing derivatives including a main adipose differentiation promotion factor inhibitor or biaryl amide as an active ingredient. Additionally, by inhibiting a main adipose differentiation promotion factor and increasing Wnt10b, the composition according to the present invention can control differentiation of adipocytes, and increase insulin resistance and glucose resistance, thereby being effectively used for treating obesity and type 2 diabetes, or hepatic steatosis.

Abstract translation: 本发明涉及用于预防或治疗肥胖症和2型糖尿病或肝脂肪变性的组合物，更具体地，涉及用于预防或治疗肥胖症和2型糖尿病或肝脂肪变性的组合物，其包含主要脂肪分化促进的衍生物 因子抑制剂或联芳基酰胺作为活性成分。 另外，通过抑制主要的脂肪分化促进因子和增加Wnt10b，本发明的组合物可以控制脂肪细胞的分化，增加胰岛素抵抗和葡萄糖耐量，从而有效地用于治疗肥胖和2型糖尿病或肝脂肪变性 。

公开(公告)号：KR1020130101493A

公开(公告)日：2013-09-13

申请号：KR1020130102400

申请日：2013-08-28

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  윤철호 ,  박민 ,  윤일주

IPC: A61K31/05 ,  A61K31/09 ,  A61P3/04 ,  A61P3/10

Abstract: PURPOSE: A use of resverastrol derivatives is provided to suppress triggering receptor expressed on myeloid cells-2 (TREM-2) and to regulate the expression of genes related to insulin metabolism and adipocyte differentiation, thereby effectively treating obesity or type 2 diabetes. CONSTITUTION: A method for suppressing TREM-2 in animals exclusive of human comprises the step of administering a composition containing one or more selected among piceatannol, piceid, and pterostilbene as active ingredients to an individual. A method for treating obesity or type 2 diabetes caused by overexpression of TREM-2 gene in animals exclusive of human comprises the step of administering the composition to an individual. A method for increasing the expression of leptin, TNFalpha gene, and adiponectin gene in a TREM-2 transgenic mouse comprises the step of administering the composition to an individual.

Abstract translation: 目的：提供使用白藜芦醇衍生物以抑制在骨髓细胞-2（TREM-2）上表达的触发受体并调节与胰岛素代谢和脂肪细胞分化相关的基因的表达，从而有效治疗肥胖或2型糖尿病。 构成：不包括人类的动物中抑制TREM-2的方法包括向个体施用含有作为活性成分的作为活性成分的作为活性成分的皮质烷醇，皮质和蝶啶中的一种或多种的组合物的步骤。 在不包括人类的动物中，TREM-2基因过表达引起的肥胖症或2型糖尿病的治疗方法包括向个体施用组合物的步骤。 在TREM-2转基因小鼠中增加瘦素，TNFα基因和脂连蛋白基因表达的方法包括向个体施用组合物的步骤。

公开(公告)号：KR1020090090952A

公开(公告)日：2009-08-26

申请号：KR1020080016531

申请日：2008-02-22

Applicant: 전남대학교산학협력단

Inventor： 강형식 ,  김은미 ,  김동헌 ,  최하림 ,  이은희 ,  김일수 ,  박민

IPC: A61K39/395 ,  A61K38/00

CPC classification number: A61K38/44 ,  A61K38/005 ,  A61K38/1774 ,  A61K39/395 ,  C12N15/62 ,  Y10S514/886

Abstract: A composition for regulating or detecting gamma-delta T cell or cytokines secreted by the gamma-delta T cell, which contains Axl receptor tyrosine kinase, its ligand or inhibitor is provided to regulate gamma-delta T cell and prevent or treat inflammatory bowl diseases (IBD). A composition for regulating gamma-delta T cell or a cytokine which is secreted by the gamma-delta T cell comprises an Axl receptor tyrosine kinase, its ligand or its inhibitor as an active ingredient. The composition is used for preventing and treating inflammatory bowel disease. A method for screening an agent for preventing and treating inflammatory bowel disease comprises: a step of adding a test compound in Axl receptor tyrosine kinase, its ligand or inhibitor; and a step of researching the influence of test compound on the expression or activation of Axl receptor tyrosine kinase, gamma-delta T cell, or cytokine secreted by the gamma-delta T cell.

Abstract translation: 提供用于调节或检测由含有Ax1受体酪氨酸激酶，其配体或抑制剂的γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物，以调节γ-δT细胞并预防或治疗炎性碗疾病（ IBD）。 用于调节由γ-δT细胞分泌的γ-δT细胞或细胞因子的组合物包含Ax1受体酪氨酸激酶，其配体或其抑制剂作为活性成分。 该组合物用于预防和治疗炎症性肠病。 用于筛选用于预防和治疗炎症性肠病的药剂的方法包括：在Ax1受体酪氨酸激酶，其配体或抑制剂中加入测试化合物的步骤; 以及研究化合物对由γ-δT细胞分泌的Axl受体酪氨酸激酶，γ-δT细胞或细胞因子的表达或活化的影响的步骤。